Skip to main content
NLS Pharmaceutics Ltd. logo

NLS Pharmaceutics Ltd. — Investor Relations & Filings

Ticker · NLSP ISIN · CH0523961370 US Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country US United States of America
Listing US NLSP

About NLS Pharmaceutics Ltd.

https://nlspharma.com/

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system (CNS) disorders. The company's primary focus areas include sleep disorders, neurodegenerative diseases, and attention-deficit/hyperactivity disorder (ADHD). Its lead product candidates are Quilience, a proprietary extended-release formulation of mazindol for the treatment of narcolepsy, and Nolazol for ADHD. NLS Pharmaceutics is also advancing its pipeline with additional assets, such as the AEX-6xx series, to address other CNS-related conditions.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a Form 6-K current report by a foreign private issuer that attaches the Notice of Meeting and Proxy Card for the Annual General Shareholders’ Meeting. These materials are sent to shareholders to provide information and request their votes for the AGM. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 87% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed under the Securities Exchange Act of 1934. It furnishes a press release as Exhibit 99.1 and contains no standalone financial statements or substantive management discussion. This is a general regulatory submission by a foreign issuer rather than a full report (10-K, IR, etc.) or a specialized category (earnings release, M&A, dividend, etc.). It therefore falls into the generic Regulatory Filings (RNS) category.
2026-05-27 English
6-K - NewcelX Ltd. (0001783036) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release titled 'NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026.' The document length is 2057 characters, which is relatively short and primarily serves to furnish a press release rather than the full financial report itself. The document does not contain detailed financial statements or substantive financial data but rather an announcement of financial results and updates. According to the 'MENU VS MEAL' rule, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement furnishing a press release and not the full annual or interim report itself.
2026-04-30 English
6-K - NewcelX Ltd. (0001783036) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release and an investor presentation as exhibits. The document length is 2285 characters, which is relatively short and mainly announces the availability of these materials rather than containing detailed financial data or full reports. The text states that the investor presentation is made available on the company's website and the press release is furnished as an exhibit. There is no substantive financial data or detailed report content within this filing itself. According to the rules, such a filing that primarily announces or furnishes materials without containing the full report or detailed financial statements should be classified as a Regulatory Filing (RNS).
2026-04-20 English
6-K - NewcelX Ltd. (0001783036) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NewcelX Ltd., with the SEC. It reports a private placement financing transaction including details of securities purchase agreements, share issuance, and warrants. The document is not an annual or quarterly report, nor an earnings release or management discussion. It is a regulatory filing reporting a capital raising event but does not itself constitute a full capital/financing update report. The document is about a financing transaction and related agreements, which fits best under Capital/Financing Update (CAP). The document length is 7477 characters, sufficient to contain substantive details of the financing. Therefore, the classification is CAP with high confidence.
2026-04-01 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NewcelX Ltd., under the Securities Exchange Act of 1934. It contains a press release about a peer-reviewed publication and a strategy update, but does not include detailed financial statements or comprehensive financial analysis. The document length is 1946 characters, which is relatively short and primarily serves as a regulatory announcement of a press release rather than a full report. There is no indication of it being an annual report, interim report, earnings release, or any other detailed financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2026-02-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.